IL17A and uterine cervix neoplasm: The expression of IL-17A was found to be higher in cervical tumor samples (Fig. 6a), 81–100 years of age (Fig. 6b), cancer stage 1 and stage 2 (Fig. 6c), African American patients (Fig. 6d), obese and extremely obese patients (Fig. 6e), and tumor grade 2 and grade 3 patients (Fig. 6f).